Stay updated on CBDV Safety & Tolerability in ASD Clinical Trial
Sign up to get notified when there's something new on the CBDV Safety & Tolerability in ASD Clinical Trial page.

Latest updates to the CBDV Safety & Tolerability in ASD Clinical Trial page
- CheckyesterdayChange DetectedThe site revision identifier in the footer changes from v3.8.0 to v3.8.1, while the clinical trial record remains unchanged.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe clinical trial record for a Phase 2 study of cannabidivarin (CBDV) for children and young adults with autism spectrum disorder is displayed, including its termination after enrolling one participant and detailed study information.SummaryDifference43%

- Check22 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check29 days agoChange DetectedAn NIH-wide banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” across NIH content.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1 on the error page.SummaryDifference0.2%

Stay in the know with updates to CBDV Safety & Tolerability in ASD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CBDV Safety & Tolerability in ASD Clinical Trial page.